The discussion on the BTRN thread has made me check into the company for mostly an education on immune system related therapies for autoimmune diseases and recent tissue transplantation and rejection. This has led me to a reading of BGEN's SEC filings, as I wanted to know about the CD40 approaches (BTW, is there a listing anywhere of what the heck all the CD #s correspond to? I have to perform an Advanced Pub Med search for each CD #, and I would like a nice wall chart for my at home computer room.). Interesting reading on BGEN, as now Joe Davie (former med school dept. chair) has the show under good control it seems to me. Now, for my question:
Is there any good reviews or primary articles whereby CD40 vs CD 2 approaches to transplanted tissue rejection are compared?
Also, in the CD40 approaches, do you see a problem potentially other non-inflammatory roles of the CD40 system, either in the adult or during development? I suspect this is the million dollar question, or at least one of them.
Anyway, thanks as always for your input, as I was doing a little schooling for myself this morning after getting the turkey going. Happy thanksgiving.
BJ |
